About: LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
Author	Monnet, Isabelle (19..-.... ; médecin) Thiberville, Luc (1956-.... ; enseignant-chercheur) Mazières, Julien (19..-....) Lantuejoul, Sylvie (1965-.... ; biologiste) Greillier, Laurent (1977-....) Scherpereel, Arnaud (1970-....) Zalcman, Gérard
Bibliographic Citation	Zalcman G., Mazieres J., Greillier L., Lantuéjoul Sylvie, Dô P., Bylicki O., Monnet I., Corre R., Audigier-Valette C., Locatelli-Sanchez M., Molinier O., Thiberville L., Urban T., Planchard D., Ligeza-Poisson C., Amour E., Morin F., Moro-Sibilot D., Scherpereel A.. LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.. Annals of Oncology, Elsevier, 2017, 28 (suppl_5,1)
Title	LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
dc:date	2017

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software